Cargando…

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker

Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qureshi, Sadaf, Chan, Nancy, George, Mridula, Ganesan, Shridar, Toppmeyer, Deborah, Omene, Coral
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874164/ https://www.ncbi.nlm.nih.gov/pubmed/35221668 http://dx.doi.org/10.1177/11772719221078774

Ejemplares similares

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis
por: Popli, Pallvi, et al.
Publicado: (2021)

Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype
por: Llanos, Adana A. M., et al.
Publicado: (2020)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade
por: Panda, Anshuman, et al.
Publicado: (2022)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
por: Sardela de Miranda, Flávia, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
por: Toppmeyer, Deborah L., et al.
Publicado: (2020)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers
por: Bilal, Erhan, et al.
Publicado: (2012)

Structure and Optimization of Checkpoint Inhibitors
por: Picardo, Sarah L., et al.
Publicado: (2019)

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
por: Uchimiak, Katarzyna, et al.
Publicado: (2022)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells
por: Omene, Coral O., et al.
Publicado: (2011)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

New biomarkers for checkpoint inhibitor therapy
por: Burdett, Nikki, et al.
Publicado: (2020)

Breaking satellite silence: human satellite II RNA expression in ovarian cancer
por: Ganesan, Shridar
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma
por: Marar, Rosalyn, et al.
Publicado: (2022)

Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model
por: Song, Haa-Na, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Xin, Yuanfang, et al.
Publicado: (2021)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Gene expression profiling identified TP53(Mut)PIK3CA(Wild) as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors
por: Cheng, Jia'Nan, et al.
Publicado: (2020)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2au24ni1qnu3naiit4rbfom59c